Neurogene (NGNE) director Noonberg received 12,050 units
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Sarah B. Noonberg (director at Neurogene Inc., NGNE) reported that they received 12,050 units on Feb 20, 2026.
- Reporting person
- Noonberg Sarah B.
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 20, 2026 | Grant or award (A) | Non-Qualified Stock Option (right to buy)On 12,050 Common Stock1 | +12,050 | - | - | 12,050 direct |
Holdings before and after
- Non-Qualified Stock Option (right to buy): 0 to 12,050 direct
Footnotes from the filing
- 1. The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Noonberg report in this NGNE Form 4?
Sarah B. Noonberg (director at Neurogene Inc., NGNE) reported that they received 12,050 units on Feb 20, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for NGNE
Across the 7 sessions after earlier NGNE headlines, the stock closed higher 0 times and lower 7 times, with a median move of 4.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NGNE | SPY |
|---|---|---|---|
| Feb 5, 2026 | Neurogene to Participate in Upcoming Investor Conferencesand 1 other headline that session | -4.7% | -1.2% |
| Jan 12, 2026 | Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome | -3.6% | +0.2% |
| Jan 5, 2026 | Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference | -8.6% | +0.7% |
| Dec 5, 2025 | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -4.2% | +0.2% |
| Nov 14, 2025 | Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates | -14.0% | -0.0% |
| Nov 13, 2025 | Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome | -14.8% | -1.7% |
Earlier insider filings at NGNE
- Feb 24, 2026SEC Form 4 filed by Director Freedland Cory S.
- Feb 24, 2026SEC Form 4 filed by Director Woods Keith
- Jun 13, 2025SEC Form 4 filed by Director Baffi Robert
- Jun 13, 2025SEC Form 4 filed by Director Woods Robert Keith
- Jun 13, 2025SEC Form 4 filed by Director Palekar Rohan
Quantisnow market dataNASDAQ
NGNE
Neurogene Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for NGNE
Full NGNE profile on Quantisnow Follow NGNE and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time